New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

What induction regimen would you consider for KMT2A-rearranged AML in a young patient with multiple medical co-morbidities who is ineligible for clinical trials?

1 Answer
Mednet MemberInvited Expert
Hematology · University of Chicago
Answered on

Given the mention of medical comorbidities and ineligibility for trials, I am going to assume that the patient cannot be treated with an intensive induction regimen. With this in mind, a lower-intensity approach such as azacitidine + venetoclax would be my recommendation. Survival outcomes in adult patients with KMT2Ar AML are modest at best, with the MD Anderson experience reporting median OS of 0.9 years and 5-year OS of 20% (Issa et al., PMID 34588432). There are limited data regarding outcomes of newly-diagnosed KMT2Ar AML specifically treated with Aza + Ven; Singh et al reported on 17 patients with a composite CR rate of 35% and median OS of 8.8 months (Singh et al., ASCO, 2025).

Of note, recently published data of Aza-Ven + revumenib f...

Join for free or sign in to see the full answer